News >

BCMA Antibody-Drug Conjugate Belantamab Mafodotin Succeeds in Phase II Myeloma Trial

OncLive Staff
Published: Friday, Aug 23, 2019

Hal Barron, MD

Hal Barron, MD

Belantamab mafodotin (GSK2857916) met the primary endpoint of demonstrating a clinically meaningful overall response rate (ORR) in patients with relapsed/refractory multiple myeloma, according to topline results from the phase II DREAMM-2 trial announced by GSK, the manufacturer of the anti-BCMA antibody-drug conjugate.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication